SCHEMBL6207867

SCHEMBL6207867

CCc1ccc(Nc2c(-c3nnc(NCCOC)o3)ccc(F)c2F)c(F)c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 8/20 0.33
KCNH2 Q12809 7/20 0.33
PIM1 P11309 1/20 0.33
CAMK2B Q13554 1/20 0.33
CHRNA1 P02708 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNA4 P43681 1/20 0.33
ADCY1 Q08828 1/20 0.32
FLT1 P17948 4/20 0.32
KDR P35968 4/20 0.32
FGFR1 P11362 2/20 0.32
MAP2K1 Q02750 3/20 0.31
TUBB4A P04350 2/20 0.31
TUBB P07437 2/20 0.31
TUBA3C P0DPH7 2/20 0.31
TUBA1B P68363 2/20 0.31
TUBA4A P68366 2/20 0.31
TUBB4B P68371 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6398977 0.89 KDR (0.34) CHRNA7KCNH2PIM1CAMK2BADCY1
SCHEMBL6205699 0.89 MAP2K1 (0.37) CHRNA7KCNH2CYP3A4ADCY1FLT1
SCHEMBL6187962 0.88 CHRNA7 (0.34) CHRNA7KCNH2PIM1CAMK2BCHRNA1
SCHEMBL6227680 0.88 CHRNA7 (0.33) CHRNA7KCNH2CHRNA1CYP3A4CYP2D6
SCHEMBL6404342 0.88 CHRNA7 (0.30) CHRNA7KCNH2
SCHEMBL6208038 0.88 PIM1 (0.45) PIM1CAMK2BMAP2K1MAP2K2
SCHEMBL6186306 0.85 CHRNA7 (0.30) CHRNA7KCNH2CYP3A4FLT1KDR
SCHEMBL6207184 0.85 FLT1 (0.39) FLT1KDR
SCHEMBL6230975 0.85 CHRNA7 (0.34) CHRNA7KCNH2CHRNA1CYP3A4CYP2D6
SCHEMBL6207302 0.84 PDCD1 (0.39) CHRNA7KCNH2CYP3A4ADCY1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578736-A1 MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL-PHENYLAMINE DERIVATIVES Warner-Lambert Company LLC (US) 2005-09-28 EP claimed
US-20050004186-A1 MEK inhibiting compounds PFIZER INC 2005-01-06 US claimed
WO-2004056789-A1 MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL PHENYLAMINE DERIVATES WARNER-LAMBERT COMPANY LLC (US) 2004-07-08 WO claimed
US-20050004186-A1 MEK inhibiting compounds PFIZER INC 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004186-A1 MEK inhibiting compounds MAPK1, MAP3K1, MAPK3 CHRNA7 4667/4885KCNH2 3852/4885PIM1 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.